Related Experiment Video
Updated: Feb 11, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma
Tom Tan-To Cheung1, Philip Chong-Hei Kwok2, Stephen Chan3
1Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Insights
This consensus provides updated guidelines for hepatocellular carcinoma (HCC) management in Hong Kong, focusing on treatment modalities for patients unsuitable for surgical resection. It emphasizes evidence-based strategies for HCC care.
Area of Science:
- Hepatology
- Oncology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) is a significant health concern in Hong Kong, largely attributed to a high prevalence of chronic hepatitis B infection.
- Liver cancer ranks as the fourth most common cancer and the third leading cause of cancer-related mortality in the region.
- The high incidence of HCC has fostered extensive local expertise and the availability of diverse treatment options.
Purpose of the Study:
- To update local consensus statements for the management of hepatocellular carcinoma (HCC).
- To provide evidence-based guidance on the utilization of various treatment modalities for HCC.
- To offer specific recommendations for managing HCC cases not amenable to surgical resection.
Main Methods:
- A multidisciplinary group of Hong Kong clinicians convened in early 2017.
- The group included specialists in liver surgery, interventional radiology, clinical oncology, and medical oncology.
- Consensus statements were updated based on the latest available evidence.
Main Results:
- Detailed guidance is provided on selecting patients for surgical resection.
- Methods to enhance patient candidacy for resection are outlined.
- Recommendations are established for employing non-surgical interventions in patients ineligible for resection.
Conclusions:
- The updated consensus statements offer comprehensive strategies for HCC management.
- Particular emphasis is placed on optimizing treatment for patients with HCC unsuitable for surgical resection.
- These guidelines aim to standardize and improve the care of HCC patients in Hong Kong.
Background:
Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong due to the high prevalence of chronic hepatitis B infection. Liver cancer is the fourth most common cancer and the third most common cause of cancer death. Due to the high case load, there is a high level of local expertise in treating HCC, and the full spectrum of treatment modalities is available. This document summarizes how these modalities should be used based on the latest evidence.
Summary:
In 2 meetings held in early 2017, a multidisciplinary group of Hong Kong clinicians, including liver surgeons, interventional radiologists, clinical oncologists, and medical oncologists, met to update local consensus statements for management of HCC. These statements are based on the latest evidence and give detailed guidance on how to deploy these modalities, in particular for cases of HCC which are not suited to surgical resection.
Key Messages:
These statements give detailed information on how to decide if a patient is a candidate for resection, methods to improve candidacy for resection, and guidance for use of various nonsurgical interventions to manage patients ineligible for resection.
Related Concept Videos
Statements of the Second Law of Thermodynamics
Tonsillitis II: Management
Impression Management Techniques I: Managing Appearances
Managing Impressions
Management of Insomnia
Angina IV: Management

